Tags

Type your tag names separated by a space and hit enter

Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management.
Turk J Gastroenterol 2014; 25(2):127-32TJ

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an umbrella term that covers both a relatively benign condition, which is simple steatosis, and nonalcoholic steatohepatitis (NASH). NASH is characterized by a chronic and progressive liver pathology that may progress to cirrhosis, end-stage liver disease, hepatocellular carcinoma, and liver transplantation. Despite the growing body of evidence, one of the important and unresolved problems is the pathogenesis of NASH. It might be a metabolic disturbance as a primary abnormality in NAFLD. Insulin resistance is at the center of these metabolic abnormalities. Then, hepatocyte injury might be induced by oxidative stress. This ongoing process progresses to NASH, even to cirrhosis in some patients. In addition to oxidative stress, possibilities for the next hit are lipid peroxidation, reactive metabolites, adipose tissue products, transforming growth factor-β₁, Fas ligand, mitochondrial dysfunction, respiratory chain deficiency, and intestinal microbiota. Currently, there is no well-established and approved therapy. Recommendations are to improve existing co-morbidities, such as obesity, hyperlipidemia, or type 2 diabetes, and lifestyle modification with weight loss and exercise.

Authors+Show Affiliations

Department of Gastroenterology, Türkiye Yüksek İhtisas Hospital, Ankara, Turkey. normeci@yahoo.com.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25003670

Citation

Başaranoğlu, Metin, and Necati Örmeci. "Nonalcoholic Fatty Liver Disease: Diagnosis, Pathogenesis, and Management." The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology, vol. 25, no. 2, 2014, pp. 127-32.
Başaranoğlu M, Örmeci N. Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management. Turk J Gastroenterol. 2014;25(2):127-32.
Başaranoğlu, M., & Örmeci, N. (2014). Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management. The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology, 25(2), pp. 127-32. doi:10.5152/tjg.2014.7675.
Başaranoğlu M, Örmeci N. Nonalcoholic Fatty Liver Disease: Diagnosis, Pathogenesis, and Management. Turk J Gastroenterol. 2014;25(2):127-32. PubMed PMID: 25003670.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management. AU - Başaranoğlu,Metin, AU - Örmeci,Necati, PY - 2014/7/9/entrez PY - 2014/7/9/pubmed PY - 2015/3/31/medline SP - 127 EP - 32 JF - The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology JO - Turk J Gastroenterol VL - 25 IS - 2 N2 - Nonalcoholic fatty liver disease (NAFLD) is an umbrella term that covers both a relatively benign condition, which is simple steatosis, and nonalcoholic steatohepatitis (NASH). NASH is characterized by a chronic and progressive liver pathology that may progress to cirrhosis, end-stage liver disease, hepatocellular carcinoma, and liver transplantation. Despite the growing body of evidence, one of the important and unresolved problems is the pathogenesis of NASH. It might be a metabolic disturbance as a primary abnormality in NAFLD. Insulin resistance is at the center of these metabolic abnormalities. Then, hepatocyte injury might be induced by oxidative stress. This ongoing process progresses to NASH, even to cirrhosis in some patients. In addition to oxidative stress, possibilities for the next hit are lipid peroxidation, reactive metabolites, adipose tissue products, transforming growth factor-β₁, Fas ligand, mitochondrial dysfunction, respiratory chain deficiency, and intestinal microbiota. Currently, there is no well-established and approved therapy. Recommendations are to improve existing co-morbidities, such as obesity, hyperlipidemia, or type 2 diabetes, and lifestyle modification with weight loss and exercise. SN - 2148-5607 UR - https://www.unboundmedicine.com/medline/citation/25003670/Nonalcoholic_fatty_liver_disease:_diagnosis_pathogenesis_and_management_ L2 - http://www.turkjgastroenterol.org/eng/makale/4331/276/Full-Text DB - PRIME DP - Unbound Medicine ER -